Nurix Therapeutics (NRIX) Competitors $10.07 -0.39 (-3.73%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$10.22 +0.15 (+1.48%) As of 04:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NRIX vs. PTGX, AAPG, HCM, KYMR, CRNX, IMVT, ALVO, MOR, OGN, and NAMSShould you be buying Nurix Therapeutics stock or one of its competitors? The main competitors of Nurix Therapeutics include Protagonist Therapeutics (PTGX), Ascentage Pharma Group International (AAPG), HUTCHMED (HCM), Kymera Therapeutics (KYMR), Crinetics Pharmaceuticals (CRNX), Immunovant (IMVT), Alvotech (ALVO), MorphoSys (MOR), Organon & Co. (OGN), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical products" industry. Nurix Therapeutics vs. Its Competitors Protagonist Therapeutics Ascentage Pharma Group International HUTCHMED Kymera Therapeutics Crinetics Pharmaceuticals Immunovant Alvotech MorphoSys Organon & Co. NewAmsterdam Pharma Protagonist Therapeutics (NASDAQ:PTGX) and Nurix Therapeutics (NASDAQ:NRIX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends. Do analysts rate PTGX or NRIX? Protagonist Therapeutics currently has a consensus price target of $67.20, indicating a potential upside of 31.87%. Nurix Therapeutics has a consensus price target of $28.87, indicating a potential upside of 186.66%. Given Nurix Therapeutics' higher probable upside, analysts plainly believe Nurix Therapeutics is more favorable than Protagonist Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protagonist Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00Nurix Therapeutics 0 Sell rating(s) 3 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.81 Which has higher earnings and valuation, PTGX or NRIX? Protagonist Therapeutics has higher revenue and earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtagonist Therapeutics$434.43M7.27$275.19M$0.7567.95Nurix Therapeutics$54.55M14.11-$193.57M-$2.61-3.86 Does the media favor PTGX or NRIX? In the previous week, Protagonist Therapeutics had 4 more articles in the media than Nurix Therapeutics. MarketBeat recorded 9 mentions for Protagonist Therapeutics and 5 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 0.94 beat Protagonist Therapeutics' score of 0.70 indicating that Nurix Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nurix Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is PTGX or NRIX more profitable? Protagonist Therapeutics has a net margin of 24.88% compared to Nurix Therapeutics' net margin of -234.57%. Protagonist Therapeutics' return on equity of 8.23% beat Nurix Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Protagonist Therapeutics24.88% 8.23% 7.47% Nurix Therapeutics -234.57%-45.26%-34.71% Which has more volatility & risk, PTGX or NRIX? Protagonist Therapeutics has a beta of 2.33, indicating that its share price is 133% more volatile than the S&P 500. Comparatively, Nurix Therapeutics has a beta of 2.14, indicating that its share price is 114% more volatile than the S&P 500. Do insiders & institutionals believe in PTGX or NRIX? 98.6% of Protagonist Therapeutics shares are held by institutional investors. 4.9% of Protagonist Therapeutics shares are held by insiders. Comparatively, 7.4% of Nurix Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryProtagonist Therapeutics beats Nurix Therapeutics on 12 of the 17 factors compared between the two stocks. Get Nurix Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NRIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NRIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRIX vs. The Competition Export to ExcelMetricNurix TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$799.66M$2.98B$5.48B$9.57BDividend YieldN/A2.46%3.99%4.17%P/E Ratio-3.8617.9729.9425.14Price / Sales14.11262.51398.9486.71Price / CashN/A41.8335.9458.58Price / Book1.357.238.105.59Net Income-$193.57M-$54.43M$3.26B$265.48M7 Day Performance-8.79%0.22%0.68%1.22%1 Month Performance-17.53%5.59%2.46%0.39%1 Year Performance-50.05%9.98%27.69%23.47% Nurix Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRIXNurix Therapeutics2.3978 of 5 stars$10.07-3.7%$28.87+186.7%-49.7%$799.66M$54.55M-3.86300Positive NewsPTGXProtagonist Therapeutics2.9632 of 5 stars$56.26+2.0%$66.10+17.5%+42.4%$3.42B$434.43M75.01120Earnings ReportAnalyst ForecastAAPGAscentage Pharma Group InternationalN/A$39.27+3.9%N/AN/A$3.30B$134.35M0.00600HCMHUTCHMED2.6468 of 5 stars$17.98+2.1%$23.50+30.7%-16.9%$3.07B$630.20M0.001,811News CoveragePositive NewsKYMRKymera Therapeutics3.4606 of 5 stars$44.20-3.5%$59.11+33.7%+1.3%$2.98B$47.07M-14.26170Positive NewsCRNXCrinetics Pharmaceuticals3.3181 of 5 stars$30.30-2.2%$69.50+129.4%-42.3%$2.90B$1.04M0.00210Positive NewsEarnings ReportIMVTImmunovant1.5403 of 5 stars$16.76-1.1%$36.40+117.2%-41.7%$2.90BN/A0.00120ALVOAlvotech2.8511 of 5 stars$9.81+2.1%$14.00+42.7%-23.3%$2.90B$491.98M16.571,032MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730OGNOrganon & Co.4.8367 of 5 stars$9.96-2.4%$18.00+80.7%-52.2%$2.65B$6.40B2.824,000Trending NewsEarnings ReportDividend AnnouncementNAMSNewAmsterdam Pharma3.4752 of 5 stars$23.42-0.8%$41.30+76.3%+46.6%$2.65B$45.56M-12.464News CoverageEarnings ReportAnalyst Forecast Related Companies and Tools Related Companies PTGX Alternatives AAPG Alternatives HCM Alternatives KYMR Alternatives CRNX Alternatives IMVT Alternatives ALVO Alternatives MOR Alternatives OGN Alternatives NAMS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NRIX) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nurix Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nurix Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
